For the quarter ended December 2023, PTC Therapeutics (PTCT - Free Report) reported revenue of $307.06 million, up 83.4% over the same period last year. EPS came in at -$0.24, compared to -$2.35 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $315.9 million, representing a surprise of -2.80%. The company delivered an EPS surprise of -182.76%, with the consensus EPS estimate being $0.29.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how PTC Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Net product revenue: $155.06 million compared to the $153.38 million average estimate based on five analysts. The reported number represents a change of +21.6% year over year.
- Revenues- Royalty revenue: $51 million compared to the $64.69 million average estimate based on five analysts.
- Revenues- Manufacturing: $0.97 million versus $97.33 million estimated by four analysts on average.
View all Key Company Metrics for PTC Therapeutics here>>>Shares of PTC Therapeutics have returned +8.1% over the past month versus the Zacks S&P 500 composite's +3.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
For the quarter ended December 2023, PTC Therapeutics (PTCT - Free Report) reported revenue of $307.06 million, up 83.4% over the same period last year. EPS came in at -$0.24, compared to -$2.35 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $315.9 million, representing a surprise of -2.80%. The company delivered an EPS surprise of -182.76%, with the consensus EPS estimate being $0.29.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how PTC Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Net product revenue: $155.06 million compared to the $153.38 million average estimate based on five analysts. The reported number represents a change of +21.6% year over year.
- Revenues- Royalty revenue: $51 million compared to the $64.69 million average estimate based on five analysts.
- Revenues- Manufacturing: $0.97 million versus $97.33 million estimated by four analysts on average.
View all Key Company Metrics for PTC Therapeutics here>>>Shares of PTC Therapeutics have returned +8.1% over the past month versus the Zacks S&P 500 composite's +3.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Get the latest research report on PTCT - FREE